Marco Tagliamento, Alessandra Gennari, Matteo Lambertini, Ramón Salazar, Nadia Harbeck, Lucia Del Mastro, Juan Aguilar‐Company, Mark Bower, Rachel Sharkey, Alessia Dalla Pria, Andrea Plaja, Amanda Jackson, Jasmine Handford, Ailsa Sita-Lumsden, Clara Martínez-Vila, Marta Matas, Ana M. Ferrero Rodriguez, Bruno Vincenzi, Giuseppe Tonini, Alexia Bertuzzi, Joan Brunet, Paolo Pedrazzoli, Francesca D’Avanzo, Federica Biello, Alasdair Sinclair, Alvin Lee, Sabrina Rossi, Gianpiero Rizzo, Oriol Mirallas, Isabel Pimentel, María Iglesias, Ana Sánchez, Annalisa Guida, Rossana Berardi, Alberto Zambelli, Carlo Tondini, Marco Filetti, Francesca Mazzoni, Uma Mukherjee, Nikolaos Diamantis, Alessandro Parisi, Avinash Aujayeb, Aleix Prat, Michela Libertini, Salvatore Grisanti, Maura Rossi, Federica Zoratto, Daniele Generali, Cristina Saura, Gary H. Lyman, Nicole M. Kuderer, David J. Pinato, Alessio Cortellini,
PURPOSE Although representing the majority of newly diagnosed cancers, patients with breast cancer appear less vulnerable to COVID-19 mortality compared with other malignancies. In the absence of patients on active cancer therapy included in vaccination trials, a contemporary real-world evaluation of outcomes during the various pandemic phases, as well as of the impact of vaccination, is needed to better inform clinical practice. METHODS We compared COVID-19 morbidity and mortality among patients ...
Tópico(s): Global Cancer Incidence and Screening
2023 - Lippincott Williams & Wilkins | Journal of Clinical Oncology
Produção Nacional
Revisado por pares
Alessio Cortellini, Massimo Di Maïo, Olga Nigro, Alessandro Leonetti, Diego Cortinovis, Joachim G.J.V. Aerts, Giorgia Guaitoli, Fausto Barbieri, Raffaele Giusti, Miriam Grazia Ferrara, Emilio Bria, Ettore D’Argento, Francesco Grossi, Erika Rijavec, Annalisa Guida, Rossana Berardi, Mariangela Torniai, Vincenzo Sforza, Carlo Genova, Francesca Mazzoni, Marina Chiara Garassino, Alessandro De Toma, Diego Signorelli, Alain Gelibter, Marco Siringo, Paolo Marchetti, Marianna Macerelli, Francesca Rastelli, Rita Chiari, Danilo Rocco, Luigi Della Gravara, Alessandro Inno, De Tursi Michele, Antonino Grassadonia, Pietro Di Marino, Giovanni Mansueto, Federica Zoratto, Marco Filetti, Daniele Santini, Fabrizio Citarella, Marco Russano, Luca Cantini, Alessandro Tuzi, Paola Bordi, Gabriele Minuti, Lorenza Landi, Serena Ricciardi, Maria Rita Migliorino, Francesco Passiglia, Paolo Bironzo, Giulio Metro, Vincenzo Adamo, Alessandro Russo, Gian Paolo Spinelli, Giuseppe Luigi Banna, Alex Friedlaender, Alfredo Addeo, Katia Cannita, Corrado Ficorella, Giampiero Porzio, David J. Pinato,
Background Some concomitant medications including antibiotics (ATB) have been reproducibly associated with worse survival following immune checkpoint inhibitors (ICIs) in unselected patients with non-small cell lung cancer (NSCLC) (according to programmed death-ligand 1 (PD-L1) expression and treatment line). Whether such relationship is causative or associative is matter of debate. Methods We present the outcomes analysis according to concomitant baseline medications (prior to ICI initiation) with putative ...
Tópico(s): Lung Cancer Treatments and Mutations
2021 - BMJ | Journal for ImmunoTherapy of Cancer
Marta Schirripa, Sara Lonardi, Chiara Cremolini, Fotios Loupakis, Lisa Salvatore, Francesca Bergamo, Carlotta Antoniotti, Anna Roma, Roberta Bertorelle, Gianluca Masi, Federica Marmorino, Daniele Rossini, G. Pasquini, Federica Zoratto, Vittorina Zagonel, Alfredo Falcone,
3524 Background: RAS mutant metastatic colorectal cancer (mCRC) patients (pts) are excluded from treatment with anti-EGFR monoclonal antibodies. Nevertheless, retrospective data from large phase III trials led to hypothesize a potential benefit from cetuximab in KRAS G13D mutant pts both in first and advanced lines of treatment (De Roock JAMA 2010, Tejpar JCO 2012). In the refractory setting, KRAS G13D mutant pts achieved a superior progression free survival (PFS) (4.0 vs. 1.9 months, HR=0.51, p=0.004) ...
Tópico(s): Cancer Genomics and Diagnostics
2014 - Lippincott Williams & Wilkins | Journal of Clinical Oncology
Alessio Cortellini, Alessandro Leonetti, Annamaria Catino, P. Pizzutillo, Biagio Ricciuti, Andrea De Giglio, Rita Chiari, Paola Bordi, Daniele Santini, Raffaele Giusti, Michele De Tursi, Davide Brocco, Federica Zoratto, Francesca Rastelli, Fabrizio Citarella, Marco Russano, Marco Filetti, Paolo Marchetti, Rossana Berardi, Mariangela Torniai, Diego Cortinovis, Elisa Sala, C. Maggioni, Alessandro Follador, Marianna Macerelli, Olga Nigro, Alessandro Tuzi, Daniela Iacono, M.R. Migliorino, Giuseppe Luigi Banna, Giampiero Porzio, Katia Cannita, Miriam Grazia Ferrara, Emilio Bria, Domenico Galetta, Corrado Ficorella, Marcello Tiseo,
Tópico(s): Colorectal Cancer Treatments and Studies
2019 - Springer Science+Business Media | Clinical & Translational Oncology
Alessio Cortellini, Ramón Salazar, Alessandra Gennari, Juan Aguilar‐Company, Mark Bower, Alexia Bertuzzi, Joan Brunet, Matteo Lambertini, Clara Maluquer, Paolo Pedrazzoli, Alvin Lee, M. Carmen Carmona-García, Thomas Newsom-Davis, Mieke Van Hemelrijck, Andrea Plaja, Alberto Zambelli, Carlo Tondini, Daniele Generali, Rossella Bertulli, Nikolaos Diamantis, Uma Mukherjee, Gianpiero Rizzo, Tamara Yu, Federica Zoratto, Riccardo Bruna, Anna Sureda, Clara Martínez-Vila, Luca Cantini, Francesca Mazzoni, Federica Grosso, Alessandro Parisi, Maristella Saponara, Aleix Prat, David J. Pinato,
IntroductionA significant proportion of patients with cancer who recover from Coronavirus Disease 2019 (COVID-19) may experience COVID-19 sequelae in the early post-infection phase, which negatively affect their continuity of care and oncological outcome. The long-term prevalence and clinical impact of the post-COVID-19 syndrome in patients with cancer are largely unknown.MethodsIn this study, we describe the time course of COVID-19 sequelae in patients with non-advanced cancers enrolled in the OnCovid ...
Tópico(s): Intensive Care Unit Cognitive Disorders
2022 - Elsevier BV | European Journal of Cancer
Alessio Cortellini, Rita Chiari, Biagio Ricciuti, Giulio Metro, Fabiana Perrone, Marcello Tiseo, Melissa Bersanelli, Paola Bordi, Daniele Santini, Raffaele Giusti, Antonino Grassadonia, Pietro Di Marino, Nicola Tinari, Michele De Tursi, Federica Zoratto, Enzo Veltri, Francesco Malorgio, Carlo Garufi, Marco Russano, Cecilia Anesi, Tea Zeppola, Marco Filetti, Paolo Marchetti, Rossana Berardi, Silvia Rinaldi, Marianna Tudini, Rosa Rita Silva, Annagrazia Pireddu, Francesco Atzori, Daniela Iacono, Maria Rita Migliorino, Giampiero Porzio, Katia Cannita, Corrado Ficorella, Sebastiano Buti,
Background Immune-related adverse events (irAEs) developed during immunotherapy with anti-PD-1 agents, could be a predictive surrogate marker of clinical benefit in patients with advanced non–small-cell lung cancer (NSCLC). Methods Patients with NSCLC, treated with anti-PD-1 agents, were retrospectively evaluated. Univariate and multivariate analyses were performed to evaluate the relationships between types of irAEs (differentiated according to system/organ involved and to single-site/multiple-site), ...
Tópico(s): Mycobacterium research and diagnosis
2019 - Elsevier BV | Clinical Lung Cancer
Alessio Cortellini, Melissa Bersanelli, Daniele Santini, Sebastiano Buti, Marcello Tiseo, Katia Cannita, Fabiana Perrone, Raffaele Giusti, Michele De Tursi, Federica Zoratto, Riccardo Marconcini, Marco Russano, Tea Zeppola, Cecilia Anesi, Marco Filetti, Paolo Marchetti, Andrea Botticelli, Alain Gelibter, Federica De Galitiis, Maria Giuseppa Vitale, Francesca Rastelli, Marianna Tudini, Rosa Rita Silva, Francesco Atzori, Rita Chiari, Biagio Ricciuti, Andrea De Giglio, Maria Rita Migliorino, Domenico Mallardo, Vito Vanella, Claudia Mosillo, Sergio Bracarda, Silvia Rinaldi, Rossana Berardi, Clara Natoli, Corrado Ficorella, Giampiero Porzio, Paolo A. Ascierto,
Background Several studies have found an association between higher body mass index (BMI) and improved clinical outcomes in cancer patients receiving programmed cell death protein-1 (PD-1)/programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors. In a previous study, we found that overweight/obese patients were significantly more likely to experience any grade immune-related adverse events (irAEs) compared to non-overweight patients. Patients and methods We conducted a 'real-life', multi centre, ...
Tópico(s): Cancer Diagnosis and Treatment
2020 - Elsevier BV | European Journal of Cancer
Alessandro Parisi, Alessio Cortellini, Michela Roberto, Olga Venditti, Daniele Santini, Emanuela Dell’Aquila, Marco Stellato, Paolo Marchetti, Mario Occhipinti, Federica Zoratto, Federica Mazzuca, Nicola Tinari, Michele De Tursi, Laura Iezzi, Clara Natoli, Margherita Ratti, Claudio Pizzo, Michele Ghidini, Giampiero Porzio, Corrado Ficorella, Katia Cannita,
Tópico(s): Metabolism, Diabetes, and Cancer
2019 - Springer Science+Business Media | Journal of Cancer Research and Clinical Oncology
Alessio Cortellini, Alessandra Gennari, Fanny Pommeret, Grisma Patel, Thomas Newsom-Davis, Alexia Bertuzzi, Margarita Viladot, Juan Aguilar‐Company, Oriol Mirallas, Eudald Felip, Alvin Lee, Alessia Dalla Pria, Rachel Sharkey, Joan Brunet, M Carmen Carmona-García, John Chester, Uma Mukherjee, Lorenza Scotti, Saoirse Dolly, Ailsa Sita-Lumsden, Daniela Ferrante, Mieke Van Hemelrijck, Charlotte Moss, Beth Russell, Elia Seguí, Federica Biello, Marco Krengli, Javier Marco‐Hernández, Gianluca Gaïdano, Andrea Patriarca, Riccardo Bruna, Elisa Roldán, María Laura Fox, Anna Pous, Frank Griscelli, Ramón Salazar, Clara Martínez-Vila, Anna Sureda, Angela Loizidou, Clara Maluquer, Annabelle Stoclin, María Iglesias, Paolo Pedrazzoli, Gianpiero Rizzo, Armando Santoro, Lorenza Rimassa, Sabrina Rossi, Nadia Harbeck, Ana Sánchez, Bruno Vincenzi, Michela Libertini, Salvatore Provenzano, Daniele Generali, Salvatore Grisanti, Rossana Berardi, Marco Tucci, Francesca Mazzoni, Matteo Lambertini, Marco Tagliamento, Alessandro Parisi, Federica Zoratto, Paola Queirolo, Raffaele Giusti, Annalisa Guida, Alberto Zambelli, Carlo Tondini, Antonio Maconi, Marta Betti, Émeline Colomba, Nikolaos Diamantis, Alasdair Sinclair, Mark Bower, Isabel Ruiz‐Camps, David J. Pinato, Georgina Hanbury, Chris Chung, Meera Patel, Gino Dettorre, Christopher C.T. Sng, Tamara Yu, Marianne Shawe‐Taylor, Hamish DC. Bain, Lauren Cooper, Lucy Rogers, Katherine Belessiotis, Cian Murphy, Samira Bawany, Saira Khalique, Ramis Andaleeb, Eleanor Apthorp, Roxana Reyes, David García-Illescas, Nadia Saoudi, Ariadna Roqué, Ricard Mesı́a, Andrea Plaja, Marc Cucurull, Federica Grosso, Vittorio Fusco, Alice Baggi, Maristella Saponara, Luca Cantini,
Fifteen percent of patients with cancer experience symptomatic sequelae, which impair post-COVID-19 outcomes. In this study, we investigated whether a proinflammatory status is associated with the development of COVID-19 sequelae.
Tópico(s): COVID-19 Clinical Research Studies
2022 - Oxford University Press | JNCI Journal of the National Cancer Institute
Alessio Cortellini, Melissa Bersanelli, Sebastiano Buti, Katia Cannita, Daniele Santini, Fabiana Perrone, Raffaele Giusti, Marcello Tiseo, Maria Michiara, Pietro Di Marino, Nicola Tinari, Michele De Tursi, Federica Zoratto, Enzo Veltri, Riccardo Marconcini, Francesco Malorgio, Marco Russano, Cecilia Anesi, Tea Zeppola, Marco Filetti, Paolo Marchetti, Andrea Botticelli, Gian Carlo Antonini Cappellini, Federica De Galitiis, Maria Giuseppa Vitale, Francesca Rastelli, Federica Pergolesi, Rossana Berardi, Silvia Rinaldi, Marianna Tudini, Rosa Rita Silva, Annagrazia Pireddu, Francesco Atzori, Rita Chiari, Biagio Ricciuti, Andrea De Giglio, Daniela Iacono, Alain Gelibter, Mario Occhipinti, Alessandro Parisi, Giampiero Porzio, Maria Concetta Fargnoli, Paolo A. Ascierto, Corrado Ficorella, Clara Natoli,
Background Recent evidence suggested a potential correlation between overweight and the efficacy of immune checkpoint inhibitors (ICIs) in cancer patients. Patients and methods We conducted a retrospective study of advanced cancer patients consecutively treated with anti-PD-1/PD-L1 inhibitors, in order to compare clinical outcomes according to baseline BMI levels as primary analysis. Based on their BMI, patients were categorized into overweight/obese (≥ 25) and non-overweight (< 25). A gender analysis was also performed, ...
Tópico(s): Childhood Cancer Survivors' Quality of Life
2019 - BMJ | Journal for ImmunoTherapy of Cancer
Alessio Cortellini, Sebastiano Buti, Daniele Santini, Fabiana Perrone, Raffaele Giusti, Marcello Tiseo, Melissa Bersanelli, Maria Michiara, Antonino Grassadonia, Davide Brocco, Nicola Tinari, Michele De Tursi, Federica Zoratto, Enzo Veltri, Riccardo Marconcini, Francesco Malorgio, Carlo Garufi, Marco Russano, Cecilia Anesi, Tea Zeppola, Marco Filetti, Paolo Marchetti, Andrea Botticelli, Gian Carlo Antonini Cappellini, Federica De Galitiis, Maria Giuseppa Vitale, Roberto Sabbatini, Sergio Bracarda, Rossana Berardi, Silvia Rinaldi, Marianna Tudini, Rosa Rita Silva, Annagrazia Pireddu, Francesco Atzori, Rita Chiari, Biagio Ricciuti, Daniela Iacono, Maria Rita Migliorino, Antônio Rossi, Giampiero Porzio, Katia Cannita, Valeria Ciciarelli, Maria Concetta Fargnoli, Paolo A. Ascierto, Corrado Ficorella,
Abstract Background Patients with a history of autoimmune diseases (AIDs) have not usually been included in clinical trials with immune checkpoint inhibitors. Materials and Methods Consecutive patients with advanced cancer, treated with anti-programmed death-1 (PD-1) agents, were evaluated according to the presence of pre-existing AIDs. The incidence of immune-related adverse events (irAEs) and clinical outcomes were compared among subgroups. Results A total of 751 patients were enrolled; median age ...
Tópico(s): PARP inhibition in cancer therapy
2019 - AlphaMed Press | The Oncologist
David J. Pinato, Daniela Ferrante, Juan Aguilar‐Company, Mark Bower, Ramón Salazar, Oriol Mirallas, Anna Sureda, Alexia Bertuzzi, Joan Brunet, Matteo Lambertini, Clara Maluquer, Paolo Pedrazzoli, Federica Biello, Alvin Lee, Christopher C.T. Sng, Raquel Liñan, Sabrina Rossi, M. Carmen Carmona-García, Rachel Sharkey, Simeón Eremiev, Gianpiero Rizzo, Hamish DC. Bain, Tamara Yu, Claudia Andrea Cruz, Marta Perachino, Nadia Saoudi, Roser Fort‐Culillas, Kris Doonga, María Laura Fox, Elisa Roldán, Federica Zoratto, Gianluca Gaïdano, Isabel Ruiz‐Camps, Riccardo Bruna, Andrea Patriarca, Marianne Shawe‐Taylor, Vittorio Fusco, Clara Martínez-Vila, Rossana Berardi, Marco Filetti, Francesca Mazzoni, Armando Santoro, Sara Delfanti, Alessandro Parisi, Paola Queirolo, Avinash Aujayeb, Lorenza Rimassa, Aleix Prat, Josep Tabernero, Alessandra Gennari, Alessio Cortellini, David J. Pinato, Joanne Evans, Judith Swallow, Alessio Cortellini, Georgina Hanbury, Chris Chung, Meera Patel, Gino Dettorre, Diego Ottaviani, Amani Chowdhury, Alvin Lee, Christopher C.T. Sng, Tamara Yu, Marianne Shawe‐Taylor, Hamish DC. Bain, Alasdair Sinclair, Lauren Cooper, Lucy Rogers, Katherine Belessiotis, Cian Murphy, Samira Bawany, Saira Khalique, Ramis Andaleeb, Mark Bower, Alessia Dalla Pria, Rachel Sharkey, Thomas Newsom-Davis, Saorise Dolly, Ailsa Sita-Lumsde, Eleanor Apthorp, Eleanor Jones, Mieke Van Hemelrijck, Charlotte Moss, Beth Russell, Eleanor Apthorp, Nikolaos Diamantis, Uma Mukherjee, Sarah Townsend, Amanda Jackson, Angela Loizidou, Martine Piccart, Aleix Prat, Claudia Andrea Cruz, Roxana Reyes, Elia Seguí, Javier Marco‐Hernández, Margarita Viladot, Josep Tabernero, Juan Aguilar‐Company, Isabel Ruiz‐Camps, María Laura Fox, David Garcia Illescas, Nadia Saoudi, Oriol Mirallas, Elisa Roldán, Joan Brunet, MCarmen Carmona Garcia, Robert Fort-Culillas, Raquel Liñan, Nadia Harbeck, Rachel Wuerstlein, Franziska Henze, Sven� Mahner, Ricard Mesı́a, Eudald Felip, Andrea Plaja, Marc Cucurull, Ramón Salazar, Anna Sureda, Clara Maluquer, Alessandra Gennari, Federica Biello, Francesca D’Avanzo, Gianluca Gaïdano, Riccardo Bruna, Andrea Patriarca, Daniela Ferrante, Lorenza Scotti, Marco Krengly, Paolo Pedrazzoli, Gianpiero Rizzo, Alexia Bertuzzi, Sabrina Rossi, Andrea Marrari, Armando Santoro, Lorenza Rimassa, Federica Grosso, Vittorio Fusco, Sara Delfanti, Antonio Maconi, Marta Betti, Bruno Vincenzi, Giuseppe Tonini, Alberto Zambelli, Carlo Tondini, Vittoria Fotia, Lorenzo Chiudinelli, Michela Franchi, Michela Libertini, Rossella Bertulli, Salvatore Provenzano, Daniele Generali, Salvatore Grisanti, Alice Baggi, Valeria Tovazzi, Corrado Ficorella, Giampiero Porzio, Alessandro Parisi, Paola Queirolo, Maristella Saponara, Raffaele Giusti, Marco Filetti, Francesca Mazzoni, Federica Zoratto, Marco Tucci, Rossana Berardi, Luca Cantini, Francesco Paoloni, Annalisa Guida, Sergio Bracarda, Clara Martínez-Vila, María Iglesias, Ana Sánchez, Matteo Lambertini, Marta Perachino, Fanny Pommeret, Émeline Colomba,
BackgroundAlthough SARS-CoV-2 vaccines immunogenicity in patients with cancer has been investigated, whether they can significantly improve the severity of COVID-19 in this specific population is undefined.MethodsCapitalizing on OnCovid (NCT04393974) registry data we reported COVID-19 mortality and proxies of COVID-19 morbidity, including post-COVID-19 outcomes, according to the vaccination status of the included patients.Results2090 eligible patients diagnosed with COVID-19 between 02/2020 and 11/ ...
Tópico(s): COVID-19 Clinical Research Studies
2022 - Elsevier BV | European Journal of Cancer
Alessio Cortellini, Marcello Tiseo, Giuseppe Luigi Banna, Federico Cappuzzo, Joachim G.J.V. Aerts, Fausto Barbieri, Raffaele Giusti, Emilio Bria, Diego Cortinovis, Francesco Grossi, Maria Rita Migliorino, Domenico Galetta, Francesco Passiglia, Daniele Santini, Rossana Berardi, Alessandro Morabito, Carlo Genova, Francesca Mazzoni, Vincenzo Di Noia, Diego Signorelli, Alessandro Tuzi, Alain Gelibter, Paolo Marchetti, Marianna Macerelli, Francesca Rastelli, Rita Chiari, Danilo Rocco, Stefania Gori, Michele De Tursi, Giovanni Mansueto, Federica Zoratto, Matteo Santoni, Marianna Tudini, Erika Rijavec, Marco Filetti, Annamaria Catino, Pamela Pizzutilo, Luca Sala, Fabrizio Citarella, Marco Russano, Mariangela Torniai, Luca Cantini, Giada Targato, Vincenzo Sforza, Olga Nigro, Miriam Grazia Ferrara, Ettore D’Argento, Sebastiano Buti, Paola Bordi, Lorenzo Antonuzzo, Simona Scodes, Lorenza Landi, Giorgia Guaitoli, Cinzia Baldessari, Luigi Della Gravara, Maria Giovanna Dal Bello, Robert A. Belderbos, Paolo Bironzo, Simona Carnio, Serena Ricciardi, Alessio Grieco, Alessandro De Toma, Claudia Proto, Alex Friedlaender, Ornella Cantale, Biagio Ricciuti, Alfredo Addeo, Giulio Metro, Corrado Ficorella, Giampiero Porzio,
Single-agent pembrolizumab represents the standard first-line option for metastatic non-small-cell lung cancer (NSCLC) patients with a PD-L1 (programmed death-ligand 1) expression of ≥ 50%. We conducted a multicenter retrospective study aimed at evaluating the clinicopathologic correlates of pembrolizumab effectiveness in patients with treatment-naïve NSCLC and a PD-L1 expression of ≥ 50%. One thousand and twenty-six consecutive patients were included. The objective response rate (ORR) was 44.5% (95% CI ...
Tópico(s): Colorectal Cancer Treatments and Studies
2020 - Springer Science+Business Media | Cancer Immunology Immunotherapy
Marta Schirripa, Sara Lonardi, Chiara Cremolini, Fotios Loupakis, Lisa Salvatore, Francesca Bergamo, Carlotta Antoniotti, Anna Roma, Roberta Bertorelle, Federica Marmorino, Daniele Rossini, G. Pasquini, Federica Zoratto, Gianluca Masi, Vittorina Zagonel, Alfredo Falcone,
Introduction:RAS mutant mCRC patients (pts) are excluded from treatment with anti-EGFR monoclonal antibodies. Nevertheless, retrospective data from large phase III trials led to hypothesize a potential benefit from cetuximab in KRAS G13D mutant pts both in first and advanced lines of treatment (De Roock JAMA 2010, Tejpar JCO 2012). In the refractory setting, KRAS G13D mutant pts achieved a superior PFS (4.0 vs 1.9 months, HR = 0.51, p = 0.004) and OS (7.6 vs 5.7 months, HR = 0.50, p = 0.005) compared to pts ...
Tópico(s): Genetic factors in colorectal cancer
2014 - Elsevier BV | Annals of Oncology
Alessandro Parisi, Alessio Cortellini, Katia Cannita, Olga Venditti, Floriana Camarda, Maria Alessandra Calegari, Lisa Salvatore, Giampaolo Tortora, Daniele Rossini, Marco Maria Germani, Alessandra Boccaccino, Emanuela Dell’Aquila, Claudia Angela Maria Fulgenzi, Daniele Santini, Michele De Tursi, Nicola Tinari, Pietro Di Marino, Pasquale Lombardi, Susana Roselló, Marisol Huerta, Ina Valeria Zurlo, Domenico Corsi, Alessandra Emiliani, N. Zanaletti, Teresa Troiani, Pasquale Vitale, Riccardo Giampieri, Filippo Merloni, Mario Occhipinti, Paolo Marchetti, Michela Roberto, Federica Mazzuca, Michele Ghidini, Alice Indini, Ingrid Garajová, Federica Zoratto, Simona Delle Monache, Giampiero Porzio, Corrado Ficorella,
: Background: The optimal anti-angiogenic strategy as second-line treatment in RAS wild-type metastatic colorectal cancer (mCRC) treated with anti-EGFR (Epidermal Growth Factor Receptor) based first-line treatment is still debated.This multicenter, real-world, retrospective study is aimed at evaluating the effectiveness of second-line Bevacizumab- and Aflibercept-based treatments after an anti-EGFR based first-line regimen. Clinical outcomes measured were: objective response rate (ORR), progression free survival ( ...
Tópico(s): Cancer Treatment and Pharmacology
2020 - Multidisciplinary Digital Publishing Institute | Cancers
Alessio Cortellini, Alex Friedlaender, Giuseppe Luigi Banna, Giampiero Porzio, Melissa Bersanelli, Federico Cappuzzo, Joachim G.J.V. Aerts, Raffaele Giusti, Emilio Bria, Diego Cortinovis, Francesco Grossi, Maria Rita Migliorino, Domenico Galetta, Francesco Passiglia, Rossana Berardi, Francesca Mazzoni, Vincenzo Di Noia, Diego Signorelli, Alessandro Tuzi, Alain Gelibter, Paolo Marchetti, Marianna Macerelli, Francesca Rastelli, Rita Chiari, Danilo Rocco, Alessandro Inno, Pietro Di Marino, Giovanni Mansueto, Federica Zoratto, Matteo Santoni, Marianna Tudini, Michele Ghidini, Marco Filetti, Annamaria Catino, Pamela Pizzutilo, Luca Sala, Mario Occhipinti, Fabrizio Citarella, Marco Russano, Mariangela Torniai, Luca Cantini, Alessandro Follador, Vincenzo Sforza, Olga Nigro, Miriam Grazia Ferrara, Ettore D’Argento, Alessandro Leonetti, Linda Pettoruti, Lorenzo Antonuzzo, Simona Scodes, Lorenza Landi, Giorgia Guaitoli, Cinzia Baldessari, Federica Bertolini, Luigi Della Gravara, Maria Giovanna Dal Bello, Robert A. Belderbos, Marco De Filippis, Cristina Cecchi, Serena Ricciardi, Clelia Donisi, Alessandro De Toma, Claudia Proto, Alfredo Addeo, Ornella Cantale, Biagio Ricciuti, Carlo Genova, Alessandro Morabito, Daniele Santini, Corrado Ficorella, Katia Cannita,
Background The role of immune-related adverse events (irAEs), as a surrogate predictor of the efficacy of checkpoint inhibitors, has not yet been described in the setting of first-line, single-agent pembrolizumab for patients with metastatic non–small-cell lung-cancer (NSCLC) with a programmed death-ligand 1 (PD-L1) expression of ≥ 50%. Patients and Methods We previously conducted a multicenter retrospective analysis in patients with treatment-naive metastatic NSCLC and a PD-L1 expression of ≥ 50% receiving ...
Tópico(s): Lung Cancer Treatments and Mutations
2020 - Elsevier BV | Clinical Lung Cancer
Sebastiano Buti, Melissa Bersanelli, Fabiana Perrone, Marcello Tiseo, Marco Tucci, Vincenzo Adamo, Luigia Stefania Stucci, Alessandro Russo, Enrica T. Tanda, Francesco Spagnolo, Francesca Rastelli, Federica Pergolesi, Daniele Santini, Marco Russano, Cecilia Anesi, Raffaele Giusti, Marco Filetti, Paolo Marchetti, Andrea Botticelli, Alain Gelibter, Mario Occhipinti, Marco Ferrari, Maria Giuseppa Vitale, Linda Nicolardi, Rita Chiari, Erika Rijavec, Olga Nigro, Alessandro Tuzi, Michele De Tursi, Pietro Di Marino, Fabio Conforti, Paola Queirolo, Sergio Bracarda, Serena Macrini, Stefania Gori, Federica Zoratto, Enzo Veltri, Barbara Di Cocco, Domenico Mallardo, Maria Grazia Vitale, Matteo Santoni, Leonardo Valerio Patruno, Giampiero Porzio, Corrado Ficorella, David J. Pinato, Paolo A. Ascierto, Alessio Cortellini,
Background Concomitant medications are known to impact on clinical outcomes of patients treated with immune checkpoint inhibitors (ICIs). We aimed weighing the role of different concomitant baseline medications to create a drug-based prognostic score. Methods We evaluated concomitant baseline medications at immunotherapy initiation for their impact on objective response rate (ORR), progression-free survival (PFS) and overall survival (OS) in a single-institution cohort of patients with advanced cancer ...
Tópico(s): Pancreatic and Hepatic Oncology Research
2020 - Elsevier BV | European Journal of Cancer
Alessio Cortellini, Marco Tucci, Vincenzo Adamo, Luigia Stefania Stucci, Alessandro Russo, Enrica T. Tanda, Francesco Spagnolo, Francesca Rastelli, Renato Bisonni, Daniele Santini, Marco Russano, Cecilia Anesi, Raffaele Giusti, Marco Filetti, Paolo Marchetti, Andrea Botticelli, Alain Gelibter, Mario Occhipinti, Riccardo Marconcini, Maria Giuseppa Vitale, Linda Nicolardi, Rita Chiari, Claudia Bareggi, Olga Nigro, Alessandro Tuzi, Michele De Tursi, Nicola Petragnani, Laura Pala, Sergio Bracarda, Serena Macrini, Alessandro Inno, Federica Zoratto, Enzo Veltri, Barbara Di Cocco, Domenico Mallardo, Maria Grazia Vitale, David J. Pinato, Giampiero Porzio, Corrado Ficorella, Paolo A. Ascierto,
Background Concomitant medications, such as steroids, proton pump inhibitors (PPI) and antibiotics, might affect clinical outcomes with immune checkpoint inhibitors. Methods We conducted a multicenter observational retrospective study aimed at evaluating the impact of concomitant medications on clinical outcomes, by weighing their associations with baseline clinical characteristics (including performance status, burden of disease and body mass index) and the underlying causes for their prescription. ...
Tópico(s): Pancreatic and Hepatic Oncology Research
2020 - BMJ | Journal for ImmunoTherapy of Cancer
David J. Pinato, Juan Aguilar‐Company, Daniela Ferrante, Georgina Hanbury, Mark Bower, Ramón Salazar, Oriol Mirallas, Anna Sureda, Andrea Plaja, Marc Cucurull, Ricard Mesı́a, Sarah Townsend, Amanda Jackson, Alessia Dalla Pria, Thomas Newsom-Davis, Jasmine Handford, Ailsa Sita-Lumsden, Eleanor Apthorp, Bruno Vincenzi, Alexia Bertuzzi, Joan Brunet, Matteo Lambertini, Clara Maluquer, Paolo Pedrazzoli, Federica Biello, Alasdair Sinclair, Samira Bawany, Saira Khalique, Sabrina Rossi, Lucy Rogers, Cian Murphy, Katherine Belessiotis, M Carmen Carmona-García, Rachel Sharkey, David García-Illescas, Gianpiero Rizzo, Marta Perachino, Nadia Saoudi, Kris Doonga, María Laura Fox, Elisa Roldán, Gianluca Gaïdano, Isabel Ruiz‐Camps, Riccardo Bruna, Andrea Patriarca, Clara Martínez-Vila, Luca Cantini, Alberto Zambelli, Raffaele Giusti, Francesca Mazzoni, Enrico Caliman, Armando Santoro, Federica Grosso, Alessandro Parisi, Paola Queirolo, Avinash Aujayeb, Lorenza Rimassa, Aleix Prat, Marco Tucci, Michela Libertini, Salvatore Grisanti, Uma Mukherjee, Nikolaos Diamantis, Vittorio Fusco, Daniele Generali, Salvatore Provenzano, Alessandra Gennari, Josep Tabernero, Alessio Cortellini, Joanne Evans, Judith Swallow, Chris Chung, Meera Patel, Gino Dettorre, Diego Ottaviani, Amani Chowdhury, Eve Merry, Neha Chopra, Alvin JX Lee, Christopher C.T. Sng, Tamara Yu, Marianne Shawe‐Taylor, Hamish DC. Bain, Yien Ning Sophia Wong, Myria Galazi, Sarah Benafif, Palma Dileo, Irina Earnshaw, Grisma Patel, Anjui Wu, Gehan Soosaipillai, Lauren Cooper, Ramis Andaleeb, Saoirse Dolly, Eleanor Apthorp, Krishnie Srikandarajah, Eleanor Jones, Mieke Van Hemelrijck, Charlotte Moss, Beth Russell, John Chester, Angela Loizidou, Martine Piccart, Claudia Andrea Cruz, Roxana Reyes, Elia Seguí, Javier Marco‐Hernández, Margarita Viladot, Simeón Eremiev, Roser Fort‐Culillas, Isabel García, Raquel Liñan, Ariadna Roqué, Nadia Harbeck, Rachel Wuerstlein, Franziska Henze, Sven Mahner, Eudald Felip, Anna Pous, Francesca D’Avanzo, Lorenza Scotti, Marco Krengli, Andrea Marrari, Sara Delfanti, Antonio Maconi, Marta Betti, Giuseppe Tonini, Giuseppina Rita Di Fazio, Carlo Tondini, Lorenzo Chiudinelli, Michela Franchi, Michela Libertini, Rossella Bertulli, Alice Baggi, Valeria Tovazzi, Corrado Ficorella, Giampiero Porzio, Maristella Saponara, Marco Filetti, Federica Zoratto, Francesco Paoloni, Rossana Berardi, Annalisa Guida, Sergio Bracarda, María Iglesias, Ana Sánchez, Marco Tagliamento, Émeline Colomba, Fanny Pommeret,
BackgroundThe omicron (B.1.1.529) variant of SARS-CoV-2 is highly transmissible and escapes vaccine-induced immunity. We aimed to describe outcomes due to COVID-19 during the omicron outbreak compared with the prevaccination period and alpha (B.1.1.7) and delta (B.1.617.2) waves in patients with cancer in Europe.MethodsIn this retrospective analysis of the multicentre OnCovid Registry study, we recruited patients aged 18 years or older with laboratory-confirmed diagnosis of SARS-CoV-2, who had a history ...
Tópico(s): COVID-19 Clinical Research Studies
2022 - Elsevier BV | The Lancet Oncology
David J. Pinato, Josep Tabernero, Mark Bower, Lorenza Scotti, Meera Patel, Émeline Colomba, Saoirse Dolly, Angela Loizidou, John Chester, Uma Mukherjee, Alberto Zambelli, Alessia Dalla Pria, Juan Aguilar‐Company, Diego Ottaviani, Amani Chowdhury, Eve Merry, Ramón Salazar, Alexia Bertuzzi, Joan Brunet, Matteo Lambertini, Marco Tagliamento, Anna Pous, Ailsa Sita-Lumsden, Krishnie Srikandarajah, Johann Colomba, Fanny Pommeret, Elia Seguí, Daniele Generali, Salvatore Grisanti, Paolo Pedrazzoli, Gianpiero Rizzo, Michela Libertini, Charlotte Moss, Joanne Evans, Beth Russell, Nadia Harbeck, Bruno Vincenzi, Federica Biello, Rossella Bertulli, Raquel Liñan, Sabrina Rossi, M. Carmen Carmona-García, Carlo Tondini, María Laura Fox, Alice Baggi, Vittoria Fotia, Alessandro Parisi, Giampero Porzio, Maristella Saponara, Claudia Andrea Cruz, David García-Illescas, Eudald Felip, Ariadna Roqué, Rachel Sharkey, Elisa Roldán, Roxana Reyes, Irina Earnshaw, Daniela Ferrante, Javier Marco‐Hernández, Isabel Ruiz‐Camps, Gianluca Gaïdano, Andrea Patriarca, Riccardo Bruna, Anna Sureda, Clara Martínez-Vila, Ana Sánchez, Luca Cantini, Marco Filetti, Lorenza Rimassa, Lorenzo Chiudinelli, Michela Franchi, Marco Krengli, Armando Santoro, Aleix Prat, Mieke Van Hemelrijck, Nikolaos Diamantis, Thomas Newsom-Davis, Alessandra Gennari, Alessio Cortellini, Judith Swallow, Chris Chung, Gino Dettorre, Neha Chopra, Alvin Lee, Christopher C.T. Sng, Yien Ning Sophia Wong, Myria Galazi, Sarah Benafif, Palma Dileo, Grisma Patel, Anjui Wu, Alasdair Sinclair, Gehan Soosaipillai, Eleanor Jones, Nikolaos Diamantis, Uma Mukherjee, Amanda Jackson, Martine Piccart, Fanny Pommeret, Johann Colomba, E. Colomba-Blameble, Aleix Prat, Claudia Andrea Cruz, Roxana Reyes, Elia Seguí, Javier Marco‐Hernández, Josep Tabernero, Juan Aguilar‐Company, Isabel Ruiz‐Camps, María Laura Fox, David Garcia Illescas, Oriol Mirallas, Elisa Roldán, Anna Carbó, Isabel García, Rachel Wuerstlein, Ricard Mesı́a, Clara Maluquer, Francesca D’Avanzo, Giuseppe Tonini, Salvatore Provenzano, Valeria Tovazzi, Corrado Ficorella, Paola Queirolo, Raffaele Giusti, Francesca Mazzoni, Federica Zoratto, Marco Tucci, Rossana Berardi, Annalisa Guida, Sergio Bracarda, María Iglesias,
BackgroundThe medium-term and long-term impact of COVID-19 in patients with cancer is not yet known. In this study, we aimed to describe the prevalence of COVID-19 sequelae and their impact on the survival of patients with cancer. We also aimed to describe patterns of resumption and modifications of systemic anti-cancer therapy following recovery from SARS-CoV-2 infection.MethodsOnCovid is an active European registry study enrolling consecutive patients aged 18 years or older with a history of solid ...
Tópico(s): Childhood Cancer Survivors' Quality of Life
2021 - Elsevier BV | The Lancet Oncology
David J. Pinato, Meera Patel, Lorenza Scotti, Émeline Colomba, Saoirse Dolly, Angela Loizidou, John Chester, Uma Mukherjee, Alberto Zambelli, Alessia Dalla Pria, Juan Aguilar‐Company, Mark Bower, Ramón Salazar, Alexia Bertuzzi, Joan Brunet, Matteo Lambertini, Marco Tagliamento, Anna Pous, Ailsa Sita-Lumsden, Krishnie Srikandarajah, Johann Colomba, Fanny Pommeret, Elia Seguí, Daniele Generali, Salvatore Grisanti, Paolo Pedrazzoli, Gianpiero Rizzo, Michela Libertini, Charlotte Moss, Joanne Evans, Beth Russell, Nadia Harbeck, Bruno Vincenzi, Federica Biello, Rossella Bertulli, Diego Ottaviani, Raquel Liñan, Sabrina Rossi, M. Carmen Carmona-García, Carlo Tondini, María Laura Fox, Alice Baggi, Vittoria Fotia, Alessandro Parisi, Giampero Porzio, Paola Queirolo, Claudia Andrea Cruz, Nadia Saoudi, Eudald Felip, Ariadna Roqué, Thomas Newsom-Davis, Rachel Sharkey, Elisa Roldán, Roxana Reyes, Federica Zoratto, Irina Earnshaw, Daniela Ferrante, Javier Marco‐Hernández, Isabel Ruiz‐Camps, Gianluca Gaïdano, Andrea Patriarca, Riccardo Bruna, Anna Sureda, Clara Martínez-Vila, Ana Sánchez, Rossana Berardi, Raffaele Giusti, Francesca Mazzoni, Annalisa Guida, Lorenza Rimassa, Lorenzo Chiudinelli, Michela Franchi, Marco Krengli, Armando Santoro, Aleix Prat, Josep Tabernero, Mieke Van Hemelrijck, Nikolaos Diamantis, Alessandra Gennari, Alessio Cortellini,
Whether the severity and mortality of COVID-19 in patients with cancer have improved in terms of disease management and capacity is yet to be defined.To test whether severity and mortality from COVID-19 among patients with cancer have improved during the course of the pandemic.OnCovid is a European registry that collects data on consecutive patients with solid or hematologic cancer and COVID-19. This multicenter case series study included real-world data from 35 institutions across 6 countries (UK, ...
Tópico(s): COVID-19 Clinical Research Studies
2021 - American Medical Association | JAMA Oncology
Marco Russano, Alessio Cortellini, Raffaele Giusti, Alessandro Russo, Federica Zoratto, Francesca Rastelli, Alain Gelibter, Rita Chiari, Olga Nigro, Michele De Tursi, Sergio Bracarda, Stefania Gori, Francesco Grossi, Melissa Bersanelli, Lorenzo Calvetti, Vincenzo Di Noia, Mario Scartozzi, Massimo Di Maïo, Paolo Bossi, Alfredo Falcone, Fabrizio Citarella, Francesco Pantano, Corrado Ficorella, Marco Filetti, Vincenzo Adamo, Enzo Veltri, Federica Pergolesi, Mario Occhipinti, Linda Nicolardi, Alessandro Tuzi, Pietro Di Marino, Serena Macrini, Alessandro Inno, Michele Ghidini, Sebastiano Buti, Giuseppe Aprile, Eleonora Lai, Marco Audisio, Salvatore Intagliata, Riccardo Marconcini, Davide Brocco, Giampiero Porzio, Marta Piras, Erika Rijavec, Francesca Simionato, Clara Natoli, Marcello Tiseo, Bruno Vincenzi, Giuseppe Tonini, Daniele Santini,
The prognostic relevance of early immune-related adverse events (irAEs) in patients affected by non-small cell lung cancer (NSCLC) upon immunotherapy is not fully understood. The Leading to Treatment Discontinuation cohort included 24 patients experiencing severe irAEs after one of two administrations of single anti-PD-1/PD-L1 in any line setting for metastatic NSCLC between November 2015 and June 2019. The control cohort was composed of 526 patients treated with single anti-PD-1/PD-L1 in any line ...
Tópico(s): Colorectal and Anal Carcinomas
2021 - Springer Science+Business Media | Cancer Immunology Immunotherapy
Alessio Cortellini, Antonio D’Alessio, Siobhan Cleary, Sebastiano Buti, Melissa Bersanelli, Paola Bordi, Giuseppe Tonini, Bruno Vincenzi, Marco Tucci, Alessandro Russo, Francesco Pantano, Marco Russano, Luigia Stefania Stucci, Maria Chiara Sergi, Martina Falconi, Maria Antonietta Zarzana, Daniele Santini, Francesco Spagnolo, Enrica T. Tanda, Francesca Rastelli, Francesca Chiara Giorgi, Federica Pergolesi, Raffaele Giusti, Marco Filetti, Francesca Lo Bianco, Paolo Marchetti, Andrea Botticelli, Alain Gelibter, Marco Siringo, Marco Ferrari, Riccardo Marconcini, Maria Giuseppa Vitale, Linda Nicolardi, Rita Chiari, Michele Ghidini, Olga Nigro, Francesco Grossi, Michele De Tursi, Pietro Di Marino, Paola Queirolo, Sergio Bracarda, Serena Macrini, Alessandro Inno, Federica Zoratto, Enzo Veltri, Chiara Spoto, Maria Grazia Vitale, Katia Cannita, Alessandra Gennari, Daniel L. Morganstein, Domenico Mallardo, Lorenzo Nibid, Giovanna Sabarese, Leonardo Brunetti, Giuseppe Perrone, Paolo A. Ascierto, Corrado Ficorella, David J. Pinato,
Abstract Purpose: No evidence exists as to whether type 2 diabetes mellitus (T2DM) impairs clinical outcome from immune checkpoint inhibitors (ICI) in patients with solid tumors. Experimental Design: In a large cohort of ICI recipients treated at 21 institutions from June 2014 to June 2020, we studied whether patients on glucose-lowering medications (GLM) for T2DM had shorter overall survival (OS) and progression-free survival (PFS). We used targeted transcriptomics in a subset of patients to explore ...
Tópico(s): Cancer Immunotherapy and Biomarkers
2023 - American Association for Cancer Research | Clinical Cancer Research
Alessio Cortellini, Josep Tabernero, Uma Mukherjee, Ramón Salazar, Anna Sureda, Clara Maluquer, Daniela Ferrante, Mark Bower, Rachel Sharkey, Oriol Mirallas, Andrea Plaja, Marc Cucurull, Ricard Mesı́a, Alessia Dalla Pria, Thomas Newsom-Davis, Mieke Van Hemelrijck, Ailsa Sita-Lumsden, Eleanor Apthorp, Bruno Vincenzi, Giuseppina Rita Di Fazio, Giuseppe Tonini, Francesco Pantano, Alexia Bertuzzi, Sabrina Rossi, Joan Brunet, Matteo Lambertini, Paolo Pedrazzoli, Federica Biello, Francesca D’Avanzo, Alvin Lee, Marianne Shawe‐Taylor, Lucy Rogers, Cian Murphy, Lauren Cooper, Ramis Andaleeb, Saira Khalique, Samira Bawany, Sarah Ahmed, M Carmen Carmona-García, Roser Fort‐Culillas, Raquel Liñan, Federica Zoratto, Gianpiero Rizzo, Marta Perachino, Kris Doonga, Gianluca Gaïdano, Riccardo Bruna, Andrea Patriarca, Clara Martínez-Vila, Ignacio Pérez Criado, Raffaele Giusti, Francesca Mazzoni, Lorenzo Antonuzzo, Armando Santoro, Alessandro Parisi, Paola Queirolo, Avinash Aujayeb, Lorenza Rimassa, Nikolaos Diamantis, Rossella Bertulli, Claudia Angela Maria Fulgenzi, Antonio D’Alessio, Isabel Ruiz‐Camps, Nadia Saoudi, David Garcia Illescas, Irene García Medina, María Laura Fox, Alessandra Gennari, Juan Aguilar‐Company, David J. Pinato, Joanne S Evans, Judith Swallow, Georgina Hanbury, Chris Chung, Meera Patel, Gino Dettorre, Katherine Belessiotis, Dolly Saorise, Eleanor Jones, Eleanor Apthorp, Charlotte Moss, Beth Russell, Sarah Townsend, Amanda Jackson, Angela Loizidou, Martine Piccart, Fanny Pommeret, E. Colomba-Blameble, Aleix Prat, Claudia Andrea Cruz, Roxana Reyes, Elia Seguí, Javier Marco‐Hernández, Margarita Viladot, Nadia Harbeck, Rachel Wuerstlein, Franziska Henze, Sven Mahner, Eudald Felip, Lorenza Scotti, Andrea Marrari, Federica Grosso, Vittorio Fusco, Sara Delfanti, Maura Rossi, Alberto Zambelli, Carlo Tondini, Lorenzo Chiudinelli, Michela Franchi, Michela Libertini, Salvatore Provenzano, Daniele Generali, Salvatore Grisanti, Alice Baggi, Valeria Tovazzi, Corrado Ficorella, Giampiero Porzio, Maristella Saponara, Marco Filetti, Marco Tucci, Rossana Berardi, Luca Cantini, Francesco Paoloni, Annalisa Guida, Sergio Bracarda, María Iglesias, Ana Sánchez, Marco Tagliamento,
BackgroundCOVID-19 sequelae can affect about 15% of patients with cancer who survive the acute phase of SARS-CoV-2 infection and can substantially impair their survival and continuity of oncological care. We aimed to investigate whether previous immunisation affects long-term sequelae in the context of evolving variants of concern of SARS-CoV-2.MethodsOnCovid is an active registry that includes patients aged 18 years or older from 37 institutions across Belgium, France, Germany, Italy, Spain, and ...
Tópico(s): COVID-19 Clinical Research Studies
2023 - Elsevier BV | The Lancet Oncology
Daniele Santini, Tea Zeppola, Marco Russano, Fabrizio Citarella, Cecilia Anesi, Sebastiano Buti, Marco Tucci, Alessandro Russo, Maria Chiara Sergi, Vincenzo Adamo, Luigia Stefania Stucci, Melissa Bersanelli, Giulia Mazzaschi, Francesco Spagnolo, Francesca Rastelli, Francesca Chiara Giorgi, Raffaele Giusti, Marco Filetti, Paolo Marchetti, Andrea Botticelli, Alain Gelibter, Marco Siringo, Marco Ferrari, Riccardo Marconcini, Maria Giuseppa Vitale, Linda Nicolardi, Rita Chiari, Michele Ghidini, Olga Nigro, Francesco Grossi, Michele De Tursi, Pietro Di Marino, Laura Pala, Paola Queirolo, Sergio Bracarda, Serena Macrini, Stefania Gori, Alessandro Inno, Federica Zoratto, Enrica T. Tanda, Domenico Mallardo, Maria Grazia Vitale, Thomas Talbot, Paolo A. Ascierto, David J. Pinato, Corrado Ficorella, Giampiero Porzio, Alessio Cortellini,
The favourable safety profile and the increasing confidence with immune checkpoint inhibitors (ICIs) might have boosted their prescription in frail patients with short life expectancies, who usually are not treated with standard chemotherapy.
Tópico(s): Palliative Care and End-of-Life Issues
2021 - BioMed Central | Journal of Translational Medicine
Laia Garrigós, Cristina Saura, Clara Martínez-Vila, Alberto Zambelli, Mark Bower, Barbara Pistilli, Matteo Lambertini, Diego Ottaviani, Nikolaos Diamantis, Ailsa Lumsden, Sònia Pernas, Daniele Generali, Elia Seguí, Gemma Viñas, Eudald Felip, Ana Sánchez, Gianpiero Rizzo, Armando Santoro, Alessio Cortellini, Ylenia Perone, John Chester, María Iglesias, Marta Betti, Bruno Vincenzi, Michela Libertini, Francesca Mazzoni, Federica Zoratto, Rossana Berardi, Annalisa Guida, Rachel Wuerstlein, Angela Loizidou, Rachel Sharkey, Juan Aguilar‐Company, Marta Matas, Chiara Saggia, Lorenzo Chiudinelli, E. Colomba-Blameble, Myria Galazi, Uma Mukherjee, Mieke Van Hemelrijck, Mar Marín, Carla Strina, Aleix Prat, Helena Pla, Eva Ciruelos, Alexia Bertuzzi, Lucia Del Mastro, Giampiero Porzio, Thomas Newsom-Davis, Isabel Ruiz‐Camps, Maria Belen Delany, Marco Krengli, Vittoria Fotia, A.A. Viansone, Neha Chopra, Margarita Romeo, Ramón Salazar, Ignacio Pérez, Francesca D’Avanzo, Michela Franchi, Manuela Milani, Fanny Pommeret, Marco Tucci, Paolo Pedrazzoli, Nadia Harbeck, Daniela Ferrante, David J. Pinato, Alessandra Gennari,
Background: Cancer patients are at higher risk of COVID-19 complications and mortality than the rest of the population. Breast cancer patients seem to have better prognosis when infected by SARS-CoV-2 than other cancer patients. Methods: We report a subanalysis of the OnCovid study providing more detailed information in the breast cancer population. Results: We included 495 breast cancer patients with a SARS-CoV-2 infection. Mean age was 62.6 years; 31.5% presented more than one comorbidity. The ...
Tópico(s): Effects of Radiation Exposure
2021 - SAGE Publishing | Therapeutic Advances in Medical Oncology
Alessio Cortellini, Sebastiano Buti, Melissa Bersanelli, Raffaele Giusti, Fabiana Perrone, Pietro Di Marino, Nicola Tinari, Michele De Tursi, Antonino Grassadonia, Katia Cannita, Alessandra Tessitore, Federica Zoratto, Enzo Veltri, Francesco Malorgio, Marco Russano, Cecilia Anesi, Tea Zeppola, Marco Filetti, Paolo Marchetti, Andrea Botticelli, Gian Carlo Antonini Cappellini, Federica De Galitiis, Maria Giuseppa Vitale, Francesca Rastelli, Federica Pergolesi, Rossana Berardi, Silvia Rinaldi, Marianna Tudini, Rosa Rita Silva, Annagrazia Pireddu, Francesco Atzori, Daniela Iacono, Maria Rita Migliorino, Alain Gelibter, Mario Occhipinti, Francesco Martella, Alessandro Inno, Stefania Gori, Sergio Bracarda, Cristina Zannori, Claudia Mosillo, Alessandro Parisi, Giampiero Porzio, Domenico Mallardo, Maria Concetta Fargnoli, Marcello Tiseo, Daniele Santini, Paolo A. Ascierto, Corrado Ficorella,
Background: We investigate the role of family history of cancer (FHC) and diagnosis of metachronous and/or synchronous multiple neoplasms (MN), during anti-PD-1/PD-L1 immunotherapy.Design: This was a multicenter retrospective study of advanced cancer patients treated with anti-PD-1/PD-L1 immunotherapy. FHC was collected in lineal and collateral lines, and patients were categorized as follows: FHC-high (in case of cancer diagnoses in both the lineal and collateral family lines), FHC-low (in case of cancer ...
Tópico(s): Multiple and Secondary Primary Cancers
2020 - Landes Bioscience | OncoImmunology
Alberto Puccini, Daniele Rossini, Valentina Daprà, Francesco Schietroma, Serena Perazzo, Anna Ceccarelli, Federica Zoratto, Manuel Costantini, Vincenzo Formica, M. Rofei, Gianluca Mauri, Erica Bonazzina, Emiliano Tamburini, Carlo Signorelli, Lorenzo Antonuzzo, Camilla Damonte, Antonino Spinelli, Giampaolo Tortora, Armando Santoro, Lisa Salvatore,
3619 Background: T4 is widely recognized as one of the most important and independent prognostic factors in adjuvant setting for CC patients. However, the optimal management in terms of adjuvant treatment in stage II (pT4N0) as well as the impact of DNA mismatch repair deficiency (dMMR) in this subset of patients remain unclear. Here, we present a large, multicenter, real-world analysis of pT4N0 CC patients. Methods: A real-world database including pts treated at 9 Italian institutions from April ...
Tópico(s): Genetic factors in colorectal cancer
2024 - Lippincott Williams & Wilkins | Journal of Clinical Oncology
Alessio Cortellini, Domenico Mallardo, Sinéad Cleary, Melissa Bersanelli, Daniele Santini, Marco Tucci, Alessandro Russo, Francesca Rastelli, Marco Filetti, Alain Gelibter, Riccardo Marconcini, Rita Chiari, Francesco Grossi, Michele De Tursi, Paola Queirolo, Federica Zoratto, Enrica T. Tanda, Giampiero Porzio, Paolo A. Ascierto, David J. Pinato,
Chronic hyperglycemia is known to induce immune dysfunctions and multiple studies has identified resistance/adherence to insulin therapy as barriers to achieving an optimal glycaemic control in patients with diabetes mellitus (DM) after front line metformin failure. How DM affects the efficacy of immune checkpoint inhibitors (ICI) is yet to be defined.
Tópico(s): Cancer Immunotherapy and Biomarkers
2021 - Elsevier BV | Annals of Oncology
Alessio Cortellini, Sebastiano Buti, Daniele Santini, Raffaele Giusti, Marcello Tiseo, Federica Zoratto, Paolo Marchetti, Melissa Bersanelli, Federica De Galitiis, Maria Giuseppa Vitale, Francesca Rastelli, Rossana Berardi, Marianna Tudini, Francesco Atzori, Daniela Iacono, Alessandro Inno, Sergio Bracarda, Clara Natoli, Paolo A. Ascierto, Corrado Ficorella,
2559 Background: In the preliminary analysis of the FAMI-L1 study, we found a significant association between family history of cancer (FHC) and better clinical outcomes with anti-PD1/PD-L1 inhibitors. Methods: We retrospectively evaluated advanced cancer patients treated with single agents PD1/PD-L1 inhibitors. Patients were categorized as follow: FHC-high (in case of at least one cancer diagnoses in both straight and collateral family line), FHC-low (in case of a cancer diagnoses in only one family ...
Tópico(s): Multiple and Secondary Primary Cancers
2019 - Lippincott Williams & Wilkins | Journal of Clinical Oncology